ADDING ABEMACICLIB TO FIRST LINE ENDOCRINE THERAPY RESULTS IN A CLINICALLY RELEVANT SURVIVAL BENEFIT FOR PATIENTS WITH HR+ HER2- ADVANCED BREAST CANCER

(sponsored)